drugset / Trial / NCT00610571
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
NaSingle-groupOpen-labelTreatment
Summary
Objectives: * To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma * To characterize any toxicity associated with the combination oral topotecan and Temodar. * To observe patients for clinical antitumor response when treated with oral topotecan and Temodar.
Timeline
- Start
- 2004-04
- Primary completion
- 2009-09
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |
| Subject | Topotecan | Small molecule | 0.75 mg/m2 | Oral |